Inflation is finally coming down, but Federal Reserve Chair Jerome Powell warned that the U.S. economy is not out of the woods yet.
In a question-and-answer session at the Economic Club of Washington, DC, the nation's top banker said that he expects the process to take some time.
“The disinflationary process, the process of getting inflation down, has begun and it’s begun in the goods sector, which is about a quarter of our economy,” he said. “But it has a long way to go. These are the very early stages.”
The comments track with Powell's previous statements that goods inflation is only part of the run-up in prices, and that services are now one of the biggest drivers of inflation.
Despite Powell sticking to his guns that inflation could be here for a while, stocks got a bump on Tuesday following the comments. Many investors appear to be holding out hope that the Fed will soon pull back on rate hikes, which would give equity markets some room to breathe.
Powell, for his part, stressed that it will likely take another full year for inflation to be brought under control. “We expect 2023 to be a year of significant declines in inflation. It’s actually our job to make sure that that’s the case,” he said.
Still, the Fed has already started moderating its stance. Earlier this month, the Fed announced a 25-basis-point hike, down from 50 basis points enacted at its previous meeting.
Smoke that filled the cabin of a Delta flight as it took off from the Atlanta airport in February was so thick the led flight attendant had trouble seeing past the first row of passengers and the pilots donned oxygen masks as a precaution.
Arjan Stephens, President of Nature's Path, discusses the company's origin, how it has evolved today and the interesting product that came from his wedding!
Small business reporter, Gene Marks, joins Cheddar to give analysis on how small businesses are tackling incoming tariffs and how it will affect the consumer.
Babylist CEO Natalie Gordon joins Cheddar to discuss how the website is helping new parents, how to make a registry and how secondhand options are available.
Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing company filed for Chapter 11 bankruptcy protection.
